The large scale Graves’ Disease (Overactive Thyroid) report has estimations of CAGR values which are very important for businesses in deciding upon the investment value over the time period. The report brings into focus studies about market definition, market segmentation, and competitive analysis in the market. The precise and state-of-the-art information provided via this marketing report helps businesses get aware about the types of consumers, consumer’s demands and preferences, their point of view about the product, their buying intentions, their response to particular product, and their varying tastes about the specific product already existing in the market.
 
Data Bridge Market Research analyses that the Graves' disease (overactive thyroid) market was valued at USD 351.55 million in 2021 and is expected to reach USD 507.65 million by 2029, registering a CAGR of 4.70% during the forecast period of 2022 to 2029.
 
 
Market Overview:
 
Graves' disease (overactive thyroid), sometimes known as Basedow's disease, is an autoimmune condition that leads to hyperthyroidism. It occurs when the body's immune cells attack the thyroid, causing excessive thyroid hormone production. Graves' disease treatment aims to inhibit thyroid hormone production and block the hormones' effects on the body. Beta-blockers including propranolol and metoprolol are frequently used as first-line treatments. These medications help to keep your heart rate in check and safeguard it until other hyperthyroidism treatments take effect. Antithyroid drugs like methimazole (Tapazole) and propylthiouracil stop the thyroid gland from producing thyroid hormone. Radioiodine therapy entails taking a single dose of radioactive iodine in the form of a pill or a liquid. Radiation kills thyroid gland cells over a period of two to three months.
 
Graves' Disease (Overactive Thyroid) Market Dynamics
 
Drivers
 
  • Increasing prevalence of Graves' disease (overactive thyroid)
    Some of the major players operating in the Graves' disease (overactive thyroid) market are:
     
The rising prevalence of Graves' disease (overactive thyroid) across the globe is estimated to enhance the market's growth. Hyperthyroidism has a number of dangerous side effects, including cardiac problems. A high heart rate, atrial fibrillation (a heart rhythm disease that raises your risk of stroke), and congestive heart failure (a condition in which your heart can't pump enough blood to satisfy your body's needs) are all symptoms.
 
 Some of the major players operating in the Graves' disease (overactive thyroid) market are:
 
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Mylan N.V. (U.S.)
  • Teva Pharmaceutical Industries Ltd. (Ireland)
  • Sanofi (France)
  • Pfizer Inc. (U.S.)
  • GlaxoSmithKline plc (U.K.)
  • Novartis AG (Switzerland)
  • Merck & Co., Inc. (U.S.)
  • Allergan (Ireland)
  • AstraZeneca (U.K.)
 
 
Browse Trending Reports:
 
 
 
 
 
 
 
 
About Data Bridge Market Research:
 
An absolute way to predict what the future holds is to understand the current trend! Data Bridge Market Research presented itself as an unconventional and neoteric market research and consulting firm with an unparalleled level of resilience and integrated approaches. We are committed to uncovering the best market opportunities and nurturing effective information for your business to thrive in the marketplace. Data Bridge strives to provide appropriate solutions to complex business challenges and initiates an effortless decision-making process. Data Bridge is a set of pure wisdom and experience that was formulated and framed in 2015 in Pune.
 
Data Bridge Market Research has more than 500 analysts working in different industries. We have served more than 40% of the Fortune 500 companies globally and have a network of more than 5,000 clients worldwide. Data Bridge is an expert in creating satisfied customers who trust our services and trust our hard work with certainty. We are pleased with our glorious 99.9% customer satisfaction rating.
 
Contact Us: -
 
Data Bridge Market Research
 
US: +1 888 387 2818
 
United Kingdom: +44 208 089 1725
 
Hong Kong: +852 8192 7475